Last reviewed · How we verify

Pharmacological cervical ripening

University Hospital, Tours · Phase 3 active Small molecule

Pharmacological cervical ripening is a Prostaglandin analog or cervical ripening agent Small molecule drug developed by University Hospital, Tours. It is currently in Phase 3 development for Cervical ripening prior to labor induction in term or near-term pregnancy, Preparation for vaginal delivery when cervical conditions are unfavorable.

Pharmacological cervical ripening uses medications to soften and dilate the cervix in preparation for labor or delivery.

Pharmacological cervical ripening uses medications to soften and dilate the cervix in preparation for labor or delivery. Used for Cervical ripening prior to labor induction in term or near-term pregnancy, Preparation for vaginal delivery when cervical conditions are unfavorable.

At a glance

Generic namePharmacological cervical ripening
SponsorUniversity Hospital, Tours
Drug classProstaglandin analog or cervical ripening agent
TargetProstaglandin receptors (EP1, EP2, EP3, FP receptors)
ModalitySmall molecule
Therapeutic areaObstetrics and Gynecology
PhasePhase 3

Mechanism of action

This approach typically employs prostaglandin analogs (such as misoprostol or dinoprostone) or other pharmacological agents that promote cervical effacement and dilation by increasing uterine contractions and cervical compliance. The medications work by stimulating prostaglandin receptors on cervical tissue and myometrium, facilitating the physiological changes necessary for vaginal delivery when labor induction is clinically indicated.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pharmacological cervical ripening

What is Pharmacological cervical ripening?

Pharmacological cervical ripening is a Prostaglandin analog or cervical ripening agent drug developed by University Hospital, Tours, indicated for Cervical ripening prior to labor induction in term or near-term pregnancy, Preparation for vaginal delivery when cervical conditions are unfavorable.

How does Pharmacological cervical ripening work?

Pharmacological cervical ripening uses medications to soften and dilate the cervix in preparation for labor or delivery.

What is Pharmacological cervical ripening used for?

Pharmacological cervical ripening is indicated for Cervical ripening prior to labor induction in term or near-term pregnancy, Preparation for vaginal delivery when cervical conditions are unfavorable.

Who makes Pharmacological cervical ripening?

Pharmacological cervical ripening is developed by University Hospital, Tours (see full University Hospital, Tours pipeline at /company/university-hospital-tours).

What drug class is Pharmacological cervical ripening in?

Pharmacological cervical ripening belongs to the Prostaglandin analog or cervical ripening agent class. See all Prostaglandin analog or cervical ripening agent drugs at /class/prostaglandin-analog-or-cervical-ripening-agent.

What development phase is Pharmacological cervical ripening in?

Pharmacological cervical ripening is in Phase 3.

What are the side effects of Pharmacological cervical ripening?

Common side effects of Pharmacological cervical ripening include Uterine hyperstimulation, Vaginal bleeding or spotting, Gastrointestinal effects (nausea, diarrhea), Fever, Maternal tachycardia.

What does Pharmacological cervical ripening target?

Pharmacological cervical ripening targets Prostaglandin receptors (EP1, EP2, EP3, FP receptors) and is a Prostaglandin analog or cervical ripening agent.

Related